July FDA Peptide Meeting Update

Yesterday's document was just a preliminary opinion. The PCAC committee will provide recommendations to the FDA at the meeting, and the FDA will make a final decision after considering PCAC's input.

The FDA just added 8 new panel members, most of whom are associated with companies that promote or prescribe peptide products. Therefore, the committee has now effectively been "stacked" to be more inclined to give favorable recommendations for peptides.

PCAC is purely advisory. Its vote is non-binding. The FDA still retains the final decision-making authority. Theoretically, if the expert panel votes "YES PEPTIDES", the FDA can still refuse to add these peptides.

However—the "FDA" is not an entity with views independent of its leadership. It reports to HHS (the U.S. Department of Health and Human Services), and HHS = RFK. So the real fight isn't "FDA vs. PCAC." It's more likely a battle between the FDA career staff and the FDA / HHS / RFK political leadership.

If RFK + HHS + a stacked panel all want approval, and only the career staff's document says "no"—then the likelihood of approval is high. The staff document here is the only completely non-binding input, and everyone above it in the decision chain wants the opposite outcome. The career staff will lose this fight.

This doesn't mean peptide approval is guaranteed. But among all the obstacles, today's document is the easiest one to overturn.$Hims & Hers Health(HIMS.US)$Defiance Daily Target 2X Long HIMS ETF(HIMZ.US)